Autoantibodies to two novel peptides in seronegative and early rheumatoid arthritis
Autor: | Wendy L. J. Hansen, Veerle Somers, Piet Stinissen, Annette H M van der Helm-van Mil, Piet Geusens, Jan T. M. Lenaerts, Liesbeth M. De Winter, Klaartje Somers, Hanna W. van Steenbergen |
---|---|
Přispěvatelé: | Interne Geneeskunde, RS: FHML non-thematic output, RS: CAPHRI - R3 - Functioning, Participating and Rehabilitation |
Jazyk: | angličtina |
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
Adult Male rheumatoid arthritis autoantibodies diagnosis Arthritis Enzyme-Linked Immunosorbent Assay Peptides Cyclic serological gap Serology rheumatoid factor Arthritis Rheumatoid 03 medical and health sciences 0302 clinical medicine Rheumatology Medicine Rheumatoid factor Humans Pharmacology (medical) anti-citrullinated protein antibodies 030203 arthritis & rheumatology biology business.industry Autoantibody early disease Anti–citrullinated protein antibody biomarkers Middle Aged medicine.disease Prognosis seronegative Anti-thyroid autoantibodies 030104 developmental biology Early Diagnosis Rheumatoid arthritis Case-Control Studies Cohort Immunology biology.protein Female business Peptides |
Zdroj: | Rheumatology, 55(8), 1431-1436 Rheumatology, 55(8), 1431-1436. Oxford University Press |
ISSN: | 1462-0324 |
Popis: | Objectives. Despite recent progress in biomarker discovery for RA diagnostics, still over one-third of RA patients-and even more in early disease-present without RF or ACPA. The aim of this study was to confirm the presence of previously identified autoantibodies to novel Hasselt University (UH) peptides in early and seronegative RA. Methods. Screening for antibodies against novel UH peptides UH-RA.1, UH-RA.9, UH-RA.14 and UH-RA.21, was performed in two large independent cohorts. Peptide ELISAs were developed to screen for the presence of antibodies to UH-RA peptides. First, 292 RA patients (including 39 early patients), 90 rheumatic and 97 healthy controls from UH were studied. Antibody reactivity to two peptides (UH-RA. 1 and UH-RA. 21) was also evaluated in 600 RA patients, 309 patients with undifferentiated arthritis and 157 rheumatic controls from the Leiden Early Arthritis Clinic cohort. Results. In both cohorts, 38% of RA patients were seronegative for RF and ACPA. Testing for autoantibodies to UH-RA. 1 and UH-RA. 21 reduced the serological gap from 38% to 29% in the UH cohort (P = 0.03) and from 38% to 32% in the Leiden Early Arthritis Clinic cohort (P = 0.01). Furthermore, 19-33% of early RA patients carried antibodies to these peptides. Specificities in rheumatic controls ranged from 82 to 96%. Whereas antibodies against UH-RA. 1 were related to remission, anti-UH-RA. 21 antibodies were associated with inflammation, joint erosion and higher tender and swollen joint counts. Conclusion. This study validates the presence of antibody reactivity to novel UH-RA peptides in seronegative and early RA. This might reinforce current diagnostics and improve early diagnosis and intervention in RA. |
Databáze: | OpenAIRE |
Externí odkaz: |